This study investigates the impact of immune-modulating factors, including granulocyte colony-stimulating factor (G-CSF) and antibiotic treatment during adjuvant chemotherapy, on survival outcomes in early-stage triple-negative breast cancer (TNBC) patients. This evidence concerns the gene CSF3 and triple-negative breast carcinoma.